Literature DB >> 9263988

Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats.

C H Gleiter1, M Brause, U Delabar, H Zebski, K U Eckardt.   

Abstract

This in vivo study investigated whether adenosine (ADO) plays a role in oxygen-dependent production of erythropoietin (EPO). Exposure of rats to 0.075% carbon monoxide (CO) for four hours was used as a stimulus for EPO production. To inhibit potential effects of ADO, rats were treated with the non-specific ADO antagonist theophylline, the selective ADO A1 receptor blockers DPCPX and KW-3902, the selective ADO A2 receptor blocker DMPX, and AOPCP, an inhibitor of 5'-ectonucleotidase, an ADO generating enzyme that is expressed on the surface of EPO producing cells. To stimulate ADO receptor activity, animals were treated with the selective ADO A1 and A2 receptor agonists CHA and CGS 21680, the ADO reuptake inhibitors dipyridamole and soluflazine and the ADO desaminase inhibitor EHNA. At doses known to interfere with ADO signal transmission in vivo, none of these substances either influenced EPO serum levels in normoxic rats or affected the approximately 30-fold rise in EPO serum levels and the increase in renal EPO mRNA after exposure to carbon monoxide. Continuous administration of theophylline to normoxic rats for seven days did not alter hematocrit, hemoglobin or EPO serum levels. Taken together, these experiments do not support the hypothesis that ADO plays an important role in the regulation of EPO production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263988     DOI: 10.1038/ki.1997.339

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Effect of endothelin-1 on erythropoietin production in a rat model under normoxia and functional carbon monoxide-induced hypoxia.

Authors:  A Grenz; J Klein; C Köhle; S Freudenthaler; B Proksch; J Wu; S Wolf; H Osswald; C H Gleiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-07-29       Impact factor: 3.000

2.  Fenoterol increases erythropoietin concentrations during tocolysis.

Authors:  C H Gleiter; K H Schreeb; S Goldbach; S Herzog; T Cunze; W Kuhn
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?

Authors:  S Freudenthaler; P Benöhr; A Grenz; T Selzer; T Schmidt; K Mörike; H Osswald; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

4.  Adenosine produced via the CD73/ecto-5'-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight.

Authors:  Burcin Ozüyaman; Zhaoping Ding; Anja Buchheiser; Patrycja Koszalka; Norbert Braun; Axel Gödecke; Ulrich K M Decking; Herbert Zimmermann; Jürgen Schrader
Journal:  Pflugers Arch       Date:  2006-02-09       Impact factor: 3.657

5.  Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production.

Authors:  Argirios E Tsantes; Stergios T Tassiopoulos; Stefanos I Papadhimitriou; Stefanos Bonovas; Nikolaos Poulakis; Athina Vlachou; Kalitsa Filioussi; Dimitrios Loukopoulos
Journal:  Eur J Clin Pharmacol       Date:  2003-08-05       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.